Stock VCYT VERACYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Veracyte, Inc.

Equities

VCYT

US92337F1075

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
19.31 USD -0.87% Intraday chart for Veracyte, Inc. -0.72% -29.81%
Apr. 15 Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating MT
Feb. 26 Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression among Patients Undergoing Active Surveillance
AQ
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
BU
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
BU
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
BU
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
BU
Veracyte: Q4 Earnings Snapshot
AQ
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
BU
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
BU
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
BU
Veracyte Completes Acquisition of C2i Genomics
BU
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
BU
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
BU
Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
AQ
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
BU
Clinical Validation Data Published in CHEST Demonstrate that Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
AQ
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
BU
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
BU
Veracyte: Q3 Earnings Snapshot
AQ
Veracyte Announces Third Quarter 2023 Financial Results
BU
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VCYT Stock
  4. News Veracyte, Inc.
  5. Press Releases